At its Q3 2026 results briefing, Botuo Biotech said it will retain POCT rapid diagnostics as its core business, expand its product matrix, accelerate domestic and overseas registrations/certifications, and advance a microfluidic fluorescent detection

2026-11-11

At its Q3 2026 results briefing, Botuo Biotech said it will retain POCT rapid diagnostics as its core business, expand its product matrix, accelerate domestic and overseas registrations/certifications, and advance a microfluidic fluorescent detection platform and high-end microfluidic chip reagent development to strengthen POCT competitiveness. The company said it is also deploying an industrial investment platform—via equity stakes, M&A and participation in industry funds—to explore frontier medical areas including brain–computer interfaces (BCI) and AI-driven healthcare, aiming to open long-term potential growth avenues.

Other News
2026-11-11

1. Graphics card prices have finally dropped; the RTX 5080 in Huaqiangbei has seen a price reduction of 4000 yuan. 2. Server DDR5 contract prices generally rose 10% to 15% in Q4, while low-capacity eMMC prices continued to decline. 3. TSMC approved

2026-11-11

U.S. stock index futures rose, with S&P 500 futures up 0.76%, Nasdaq 100 futures up 1.67%, and Dow Jones futures up 0.25%.